TALWIN NX
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TALWIN NX (TALWIN NX).
Pentazocine is a mixed agonist-antagonist opioid analgesic that acts as an agonist at kappa opioid receptors and as an antagonist or partial agonist at mu opioid receptors. Naloxone is added to prevent intravenous abuse but has no oral bioavailability.
| Metabolism | Primarily hepatic via conjugation and oxidative pathways; CYP3A4 and CYP2C19 are involved in N-demethylation. |
| Excretion | Renal: ~60% as unchanged drug and glucuronide conjugates. Biliary/fecal: ~20% as metabolites. Total: 80% eliminated within 72 hours. |
| Half-life | 2-3 hours (terminal) for pentazocine; naloxone half-life 1-1.5 hours. Clinically, duration limited by pentazocine's shorter half-life. |
| Protein binding | Pentazocine: ~60% bound to albumin. Naloxone: ~45% bound to plasma proteins. |
| Volume of Distribution | Pentazocine: 5-7 L/kg; indicates extensive tissue distribution. Naloxone: 2.5-3 L/kg. |
| Bioavailability | Oral: ~20% (due to extensive first-pass metabolism). Parenteral: 100% (IV/IM). |
| Onset of Action | Oral: 15-30 minutes; IM: 15-20 minutes; IV: 2-3 minutes. |
| Duration of Action | Oral: 3-4 hours; IM/IV: 2-3 hours. Note: Naloxone component reduces abuse potential but does not prolong analgesia. |
| Molecular Weight | 327.4 |
1 tablet (pentazocine 50 mg/naloxone 0.5 mg) orally every 3-4 hours as needed for pain; maximum 12 tablets per day.
| Dosage form | TABLET |
| Renal impairment | For GFR 30-50 mL/min: administer every 4-6 hours. For GFR 10-29 mL/min: administer every 6-8 hours. For GFR <10 mL/min: administer every 8-12 hours. |
| Liver impairment | Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce dose by 50% and extend dosing interval to every 6 hours. Child-Pugh Class C: avoid use. |
| Pediatric use | Not recommended for use in pediatric patients; safety and efficacy not established. |
| Geriatric use | Start with half of the usual adult dose (0.5 tablet) every 4-6 hours; titrate cautiously due to increased sensitivity and risk of respiratory depression and urinary retention. |
| 1st trimester | Contraindicated in first trimester due to risk of neural tube defects and cardiovascular malformations from opioid exposure. |
| 2nd trimester | Use only if clearly indicated; may cause fetal dependence and withdrawal, but teratogenic risk is lower than t1. |
| 3rd trimester | Avoid in third trimester, especially near term, as it can cause neonatal withdrawal syndrome, respiratory depression, and meconium aspiration. |
Clinical note
Comprehensive clinical and safety monograph for TALWIN NX (TALWIN NX).
| Placental transfer | High; crosses placenta rapidly and distributes to fetal tissues, including brain, with fetal/maternal ratio ~0.8. |
| Breastfeeding | Excreted in breast milk; may cause neonatal opioid withdrawal, respiratory depression, and fetotoxicity. Use caution and monitor infant for drowsiness, difficulty feeding, and breathing. |
■ FDA Black Box Warning
Concomitant use with alcohol or CNS depressants may cause severe respiratory depression. Risk of respiratory depression, abuse, and misuse. Accidental ingestion can be fatal, especially in children.
| Serious Effects |
Hypersensitivity to naloxone or pentazocineAcute or severe bronchial asthmaUpper airway obstructionSuspected or known mechanical gastrointestinal obstructionAcute alcoholism with respiratory depressionUse within 14 days of MAOI therapyHead injury with elevated intracranial pressureParalytic ileusSevere respiratory depression
| Precautions | Respiratory depression; drug dependence and abuse potential; neonatal withdrawal syndrome with prolonged use; severe hypotension; increased intracranial pressure; risks of serotonin syndrome when used with serotonergic drugs; severe injection site reactions (including necrosis) with repeated intramuscular or subcutaneous administration. |
| Food/Dietary | No specific food interactions. Avoid alcohol as it may enhance CNS depression. |
Loading safety data…
| Lactation Rating | L4 - Possibly Hazardous |
| Teratogenic Risk | FDA Pregnancy Category C. First trimester: Limited human data; animal studies show increased risk of skeletal anomalies and fetal resorption. Second/third trimester: Chronic use may cause neonatal opioid withdrawal syndrome (NOWS), respiratory depression, and low birth weight. High doses near term can lead to neonatal respiratory depression. |
| Fetal Monitoring | Monitor maternal respiratory status, level of consciousness, and signs of opioid withdrawal. Fetal monitoring: Nonstress test and biophysical profile for prolonged use. Assess neonatal abstinence syndrome (NAS) signs post-delivery with chronic use. |
| Fertility Effects | May impair fertility in females by disrupting menstrual cycle and ovulation via opioid effects on hypothalamic-pituitary-gonadal axis. In males, potential for decreased libido and erectile dysfunction. |
| Clinical Pearls | Talwin NX contains pentazocine, a mixed agonist-antagonist opioid, and naloxone, added to deter abuse. It can precipitate withdrawal in opioid-dependent patients. Respiratory depression is less than with full agonists but may increase with higher doses. Use with caution in patients with renal or hepatic impairment. |
| Patient Advice | This medication contains naloxone to prevent abuse; do not crush or inject as it may cause severe withdrawal. · May cause dizziness, drowsiness, or constipation; avoid driving or operating heavy machinery until effects are known. · Take as prescribed; do not increase dose or frequency without consulting your doctor. · Avoid alcohol and other CNS depressants (e.g., benzodiazepines) as they may increase side effects. · Report any signs of respiratory depression (slow/shallow breathing), severe sedation, or withdrawal symptoms (nausea, sweating, agitation) immediately. |